FRET ͉ G protein-coupled receptor ͉ time-resolved signaling ͉ real-time binding ͉ ligand-receptor interaction P arathyroid hormone (PTH) is an 84-aa peptide that regulates concentrations of calcium and phosphate in blood and is of paramount importance in renal and bone metabolism (1). PTH is secreted from the parathyroid glands in response to hypocalcemia and elicits its physiological effects in kidney and bone through the activation of a G protein-coupled receptor, the PTH͞PTH-related receptor (PTHR) (2). In response to PTH this receptor leads to activation of adenylyl cyclases (via G s protein) that in turn increase the intracellular second messenger cAMP, which activates the protein kinase A (PKA)-signaling pathway. PTHR also activates the phospholipase C͞protein kinase C-signaling pathways (via G q protein), although less efficiently than the PKA-signaling pathway (3). PTH(1-34), a synthetic PTH fragment with the first 34 aa of PTH that holds the same pharmacological properties in regard to the regulation of calcium homeostasis as the full-length hormone (4), has recently become a drug (the generic name is teriparatide) approved by the U.S. Food and Drug Administration to treat osteoporosis (5, 6). The resolution of the mode of interaction of PTH(1-34) to its receptor is critical for understanding the mechanism of action of the hormone and for further progressing in drug development to treat osteoporosis.
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arathyroid hormone (PTH) is an 84-aa peptide that regulates concentrations of calcium and phosphate in blood and is of paramount importance in renal and bone metabolism (1) . PTH is secreted from the parathyroid glands in response to hypocalcemia and elicits its physiological effects in kidney and bone through the activation of a G protein-coupled receptor, the PTH͞PTH-related receptor (PTHR) (2) . In response to PTH this receptor leads to activation of adenylyl cyclases (via G s protein) that in turn increase the intracellular second messenger cAMP, which activates the protein kinase A (PKA)-signaling pathway. PTHR also activates the phospholipase C͞protein kinase C-signaling pathways (via G q protein), although less efficiently than the PKA-signaling pathway (3) . PTH(1-34), a synthetic PTH fragment with the first 34 aa of PTH that holds the same pharmacological properties in regard to the regulation of calcium homeostasis as the full-length hormone (4) , has recently become a drug (the generic name is teriparatide) approved by the U.S. Food and Drug Administration to treat osteoporosis (5, 6) . The resolution of the mode of interaction of PTH(1-34) to its receptor is critical for understanding the mechanism of action of the hormone and for further progressing in drug development to treat osteoporosis.
We recently showed that activation of PTHR by binding of PTH proceeds by fast conformational changes (time constant Ϸ 1 s) as the receptor switches from a resting to an active state (7) . To further our understanding on the PTHR interaction process we resolved the temporal events of PTH(1-34) binding to PTHR in living cells. We measured kinetics of association by FRET between tetramethyl-rhodamine (TMR) (the acceptor fluorophore) conjugated to PTH and GFP (the donor fluorophore) inserted into the N-terminal domain of the receptor (Fig.  1A) . This study reports the analysis of these kinetics and reveals a two-step process for PTH binding, where the first phase mirrored agonist binding to the receptor N-domain with a fast association rate and the second phase reflected association to the J-domain, exhibiting much slower kinetics but temporally coupled to receptor activation.
Materials and Methods
Peptides. Human PTH TMR ] was synthesized by Genemed Synthesis (San Francisco). Human [Lys-13(N -5-carboxy-TMR)]PTH(1-34)NH 2 used in preliminary experiments (data not shown) was also synthesized in our laboratory by the solid-phase approach with fluorenylmethoxycarbonyl chemistry (Supporting Text, which is published as supporting information on the PNAS web site).
[Aib 1, 3 ,M]PTH (1-14) (peptide sequence Aib-V-Aib-E-I-Q-L-M-H-Q-Har-A-K-W-NH 2 ) was kindly provided by T. Gardella (Massachusetts General Hospital and Harvard Medical School, Boston); [Aib 1, 3 ,M] refers to the combined modifications of Aib 1,3 , Gln-10, Har 11 , Ala-12, and Trp-14 on human PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , where Aib is the ␣-amino-isobutyric acid and Har is homoarginine (8) .
Note that deletion of exon 2 in PTHR does not alter the receptor pharmacology (10) . The construct verified by restriction enzyme mapping and sequencing was subcloned into pcDNA3 (Invitrogen) for transient and stable expression in human embryonic kidney (HEK)293 cells. N-terminally GFP-tagged ␤ 2 -adrenergic receptor construct ( GFP N-␤ 2 AR) in pcDNA3 was kindly provided by U. Zabel (University of Würzburg) and stably transfected into HEK293 cells for control experiments.
HEK293 cells were cultivated and transfected as described (11) . After selection with 400 g͞ml G418 (Merck), stable cell clones showing membrane expression of the GFP-tagged receptors were selected. The HEK293 cell line stably expressing the WT PTHR was kindly provided by E. Blind (University of Würzburg) (12) .
Confocal Microscopy. HEK293 cells stably expressing GFP N-PTHR or WT PTHR were plated onto poly-D-lysine-coated glass coverslips. Cells were incubated with 1 M PTH(1-34) or 1 M PTH TMR for different times, washed with PBS, and fixed for 10 min in 4% paraformaldehyde. Fixed cells were observed with an oil immersion ϫ63 Plan-Neofluar objective in a Leica TCS laser scanning microscope.
Pharmacology. Ligand binding and measurement of cAMP were performed as described (11) with minimal modifications. For binding studies, stably transfected cells grown in 24-well plates were incubated in DHB buffer (serum-free DMEM containing 20 mM Hepes and 1% BSA) for 1 h at 0°C, followed by a 1.5-h incubation with the same buffer containing 125 I-PTH(1-34) (100,000 cpm per well) as a radioligand with or without varying concentrations of unlabeled peptides. Cells were washed three times with iced PBS and extracted with 0.8 M NaOH, and cell-associated 125 I-PTH(1-34) was counted.
For cAMP assays, cells grown in 12-well plates were washed twice with Hepes buffer (137 mM NaCl͞5 mM KCl͞1 mM CaCl 2 ͞1 mM MgCl 2 ͞20 mM Hepes, pH 7.4) and incubated with isobutylmethylxanthine (0.5 mM) in the same buffer for 5 min at 37°C. Cells were stimulated with varying concentrations of PTH(1-34) or PTH(1-34) TMR at 37°C for 15 additional min. Cellular cAMP was extracted and measured by RIA (Immunotech, Luminy, France; Beckman Coulter). Competition binding studies and concentration-response data were analyzed with the program PRISM 4.0 (GraphPad, San Diego).
Microscopic FRET Measurements. FRET experiments were performed as described (7) with some modifications. In brief, cells plated on poly-D-lysine-coated glass coverslips maintained in Hepes buffer containing 0.1% (wt͞vol) BSA were placed at room temperature on a Zeiss inverted microscope (Axiovert135) equipped with an oil immersion ϫ100 Plan-Neofluar objective and a dual emission photometric system (TILL Photonics, Planegg, Germany). Cells were excited with light from a polychrome IV (TILL Photonics). The illumination time was typically set to 25 ms applied TMR was continuously superfused, and the presence of TMR fluorescence in the FRET channel (emission at 580 nm) caused by the direct excitation of TMR [i.e., bound and unbound PTH TMR ] at 480 nm does not permit the differentiation of the TMR emission caused by FRET or direct excitation. Because the diminution of GFP fluorescence was caused by FRET between GFP and TMR (see below) we used the decline of GFP fluorescence as readout for the binding event. The spillover of TMR into the 520-nm channel (2%) was negligible at PTH(1-34) TMR concentrations Ͻ3 M and subtracted from the signal of the 520-nm channel at concentrations of 3 M or higher to give a corrected F GFP . FRET between GFP N-PTHR and PTH(1-34) TMR was also determined by donor (GFP) recovery after acceptor (TMR) photobleaching after three consecutive cycles of 6 min of continuous illumination at 550 nm (orange glass 530 nm, beam splitter 555 DCLP, emission filter HQ605͞75).
Recording of Ligand-Induced Changes in FRET.
A single cell expressing GFP N-PTHR was continuously superfused with Hepes͞BSA buffer and PTH TMR at different concentrations with a computerassisted solenoid valve rapid superfusion device (ALA-VM8, ALA Scientific Instruments, Westbury, NY, solution exchange 5-10 ms, ref. 7) . Signals detected by avalanche photodiodes were digitalized with an AD converter (Digidata1322A, Axon Instruments, Union City, CA) and stored on a personal computer by using CLAMPEX 9.0 software (Axon Instruments). The change in the fluorescence emission of GFP as a function of time caused by FRET was analyzed by using nonlinear regression to one-and two-exponential models,
where A 1 and A 2 are the amplitudes of the two phases, A 0 is the baseline at t ϭ ϱ, k 1 and k 2 are the rate constants (s Ϫ1 ) for the two phases, and t is the time. The best fits were judged by the analysis of residuals (i.e., differences between the experimental data and the calculated curve fits). Changes in emission caused by photobleaching were systematically subtracted. Data were analyzed with ORIGIN 6.1 software (Microcal, Amherst, MA).
Recording cAMP Response by FRET Measurements and Cell Imaging.
HEK293 cells stably expressing PTHR were transiently transfected with the previously described Epac-based cAMP sensor (Fig. 7 , which is published as supporting information on the PNAS web site) (13) . Cells plated on poly-D-lysine-coated glass coverslips maintained in Hepes͞BSA buffer were placed at room temperature on a Zeiss inverted microscope (Axiovert135) equipped with an oil immersion ϫ63 Plan-Neofluar objective and a dual-emission imaging acquisition system coupled to a CoolSNAP-HQ chargecoupled device camera (Visitron Systems, Puchheim, Germany). Samples were excited with a light from a polychrome IV (Till Photonics). Continuous superfusion of the cells with Hepes͞BSA buffer and PTH(1-34) was performed as described (13) . FRET signals were monitored by using METAFLUOR 5.0 software (Visitron Systems), as the emission ratio at 535 Ϯ 20 nm (acceptor, enhanced yellow fluorescent protein, YFP) and 480 Ϯ 15 nm (donor, enhanced cyan fluorescent protein, CFP) (beam splitter 505 DCXR) upon donor excitation at 436 Ϯ 10 nm. The imaging data were analyzed with METAMORPH 5.0 (Visitron Systems) and ORIGIN 6.1 (Microcal) and corrected for spillover of CFP into the 535-nm channel, direct YFP excitation, and acceptor photobleaching to give a corrected ratio F YFP ͞F CFP .
Results and Discussion
Functional Characterization of GFP N-PTHR and PTH(1-34) TMR . To study the association between PTH(1-34) and PTHR, we designed and characterized a fluorescent PTH(1-34) where the TMR fluorophore was attached to the Lys side chain at position 13 in PTH(1-34) and a fluorescent PTHR where GFP was introduced into the amino-terminal domain of the receptor (Fig. 1 A) . The functional properties of PTH(1-34) TMR and GFP N-PTHR stably expressed in HEK293 cells were characterized along three different lines of experiments. First, confocal microscopy showed that GFP N-PTHR was well expressed at the plasma membrane and underwent time-dependent internalization upon incubation with PTH(1-34) (Fig. 1B Top) . PTH(1-34) TMR specifically decorated the cell surface of cells expressing PTHR and internalized with kinetics similar to that observed for GFP N-PTHR in response to PTH(1-34) (Fig. 1B  Middle and Bottom) .
Second, binding competition experiments showed that the affinity of PTH(1-34) TMR (K i ϭ 47.5 Ϯ 1.1 nM) was close to that of PTH(1-34) for GFP N-PTHR (K i ϭ 22.3 Ϯ 1.1 nM) ( Fig. 2A and Table 1 , which is published as supporting information on the PNAS web site) and approximately 1 order of magnitude lower than that of PTH(1-34) for the WT PTHR (K i ϭ 2.4 Ϯ 0.1 nM) (7) . The presence of GFP in the N-terminal domain of the receptor is presumably responsible for the loss in binding affinity.
Third, the ability of PTH(1-34) TMR to stimulate maximal cAMP responses in cells expressing the WT PTHR or GFP N-PTHR was indistinguishable from that of PTH(1-34) (Fig. 2 B and C and Table  1 ), although hormone potencies were reduced for cells expressing GFP N-PTHR (half-maximally effective concentrations, EC 50 ranged between 0.10 and 0.20 nM for PTHR and between 4 and 6 nM for GFP N-PTHR) (compare Fig. 2 B and C and Table 1 ). Taken together, these data indicate the GFP N-PTHR has, in comparison to the WT PTHR, slight altered binding and activation properties and thus is well suited for studying the association of hormone and receptor.
High Resolution of Binding Kinetics. Kinetics of binding of PTH(1-34) TMR to
GFP N-PTHR were recorded under a fluorescence microscope at the single-cell level. Fig. 1 A illustrates the principle of the experiment. After excitation at 480 nm the maximal fluorescence of GFP was recorded at 520 nm and rapid (Ͻ10 ms) addition of PTH(1-34) TMR (1 M) led to a strong and fast decrease in GFP emission (Fig. 3A Left) : the latter decreased by 15% with a half-time t 1/2 ϭ 700 Ϯ 20 ms (n ϭ 14). Photo-destruction (i.e., photobleaching) of TMR verified that the decrease in GFP fluorescence was caused by FRET: when GFP (the donor) and TMR (the acceptor) exhibited FRET, then photobleaching of TMR by direct excitation at 550 nm should increase GFP emission at 515 nm. TMR photobleaching of TMR led to recovery of the GFP emission. Control experiments where TMR was not photobleached demonstrated that the fluorescence emission of GFP and TMR moieties was stable over the time frame of the experiments (Fig. 3B Right) .
In the following experiments we proved that the decrease in GFP emission corresponds to a specific interaction between PTH(1-34) TMR and GFP N-PTHR. First, we investigated the effect of PTH(1-34) TMR on GFP N-␤ 2 AR, which was also well expressed at the cell surface and functionally active but that does not bind PTH(1-34) nor PTH(1-34) TMR (data not shown). As shown in Fig.  3A Center, the addition of PTH(1-34) TMR (1 M) had no effect on the fluorescence intensity of GFP because of the absence of FRET between PTH(1-34) TMR and GFP N-␤ 2 AR. The second experiment showed that sequential addition of PTH(1-34) (1 M) followed by PTH(1-34) TMR (1 M) to GFP N-PTHR almost completely prevented the FRET signal, indicating specificity of the response and that little, if any, agonist dissociation occurs during the experiments (Fig. 3A Right) . These data demonstrated that the change in GFP emission caused by FRET can be used to specifically record the association between GFP N-PTHR and PTH(1-34) TMR .
Two-Step Binding Mechanism to Switch On PTHR.
Recording the temporal resolution of the FRET signal from a single cell with increasing concentrations of PTH(1-34) TMR allows the kinetic analysis of the interaction of hormone and receptor (Fig. 4A) . Binding responses were well fitted to a two-exponential model (Fig.  4B) . The biphasic nature of the signal suggests that the association of PTH(1-34) to PTHR involves two binding events. At a maximal concentration of PTH(1-34) TMR (15 M) the signal rapidly reached equilibrium (t 1/2 Ϸ 120 ms), and the binding responses followed the sum of two exponential components with time constants 1 ϭ 140 Ϯ 8 ms (n ϭ 14) for the fast step and 2 ϭ 1.2 Ϯ 0.1 s (n ϭ 14) for the slower step.
Analysis of the first fast phase showed that the observed rate constant (k obs fast ) linearly depends on hormone concentration (Fig.  5A) . The strict linearity of the rate constant implies that the first step reflects a simple bimolecular interaction between the hormone (H) and its receptor (R) described by the following reaction,
where k 1 and k Ϫ1 represent the binding and dissociation rate constants, respectively, and the time course of the interaction is defined by k obs fast ϭ k Ϫ1 ϩ k 1 ϫ [H] under pseudofirst-order conditions (14) . The slope of k obs fast versus the concentration of hormone gave an association rate constant k 1 ϭ (0.7 Ϯ 0.1) ϫ 10 6 M Ϫ1 ⅐s Ϫ1 , which is too low to be under diffusion control (10 8 to 10 9 M Ϫ1 ⅐s Ϫ1 ) but was within the range for interactions between protein-protein or peptide-receptor (10 5 to 10 6 M Ϫ1 ⅐s Ϫ1 ) (15, 16) . The intercept with the ordinate axis gave a dissociation rate constant of k Ϫ1 ϭ 0.04 Ϯ 0.01 s Ϫ1 , reflecting the slow dissociation of the bound hormone. The ratio (k Ϫ1 ͞k 1 ) yielded a dissociation constant (K D ) of 50 nM, which is consistent with the value obtained from radioligand binding analysis (K i ϭ 47.5 nM).
In contrast, the rate constant of the slow phase (k obs slow ) followed a hyperbolic dependence on hormone concentrations and reached a constant value at saturating concentrations (Fig. 5) . This behavior is consistent with the following two-step reaction
in which the fast binding step is followed by a slower conformational change (denoted by * ) and where the time course is defined by
. At low hormone concentrations, the rate constants increased linearly with hormone concentrations (Fig. 5B) , indicating that the hormone binding to PTHR was the rate-limiting step as observed for the first binding step. But at high hormone concentrations the rate constants approached a maximal value, suggesting that a step other than the association of hormone receptor became ratelimiting. The time constant required for this step was Ϸ1 s (Fig. 5 ). This step is consistent with a conformational change of the bound agonist. Presumably the bound PTH(1-34) is reoriented to reach its final conformation. The kinetic profile observed for the second binding step coincides with that recently reported for the activation switch of the PTHR (Fig. 5 and ref. 7) , also recorded in a single cell with a similar FRET approach using the receptor sensor PTHR CFP/YFP (Fig. 7) . At high concentrations of hormone, rate constants governing the conformational change in the second binding step and in receptor activation were in the same range k obs slow ϭ 0.80-0.98 s Ϫ1 (n ϭ 14) for binding and k obs ϭ 0.86-1.03 s Ϫ1 (n ϭ 10) for receptor activation (7) . These kinetic similarities between the second association step and receptor activation suggest that these two events might be coupled.
To explore the possibility that the slow step of binding related to receptor activation we used [Aib 1, 3 , M]PTH(1-14) (see Materials and Methods), a conformationally constrained PTH(1-14)-derived agonist with increased ␣-helicity and similar binding and signaling properties as PTH(1-34) (8, 18) . Extensive studies have demonstrated that [Aib 1, 3 , M]PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and other PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) analogs (8, (19) (20) (21) mainly, if not exclusively, bind to the PTHR J-domain in contrast to PTH(1-34), which binds to both receptor's N-and J-domains (22) . When [Aib 1, 3 , M]PTH (1-14) is bound, it prevents PTH analogs from occupying their binding site at the J-domain of the receptor (8, 18) . In the next experiment, we examined whether the specific association of [Aib 1, 3 , M]PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) to the receptor J-domain is able to differentiate the two kinetically distinct phases were directly proportional to the agonist concentration, whereas k obs values for the second step (k obs slow , ‚) followed an hyperbolic dependence on agonist concentration and reach a constant value k obs Ϸ0.8 s Ϫ1 . Results for rate constants for PTHR activation (F) originate from our previous study (7) . ( of PTH(1-34) TMR binding to GFP N-PTHR. As we observed in Fig.  4B, PTH(1-34) TMR (3 M) association was described by the sum of two exponential phases with association rate constants (k obs ) of 2.30 Ϯ 0.14 s Ϫ1 and 0.38 Ϯ 0.04 s Ϫ1 (n ϭ 12) for the first and second phases, respectively. The corresponding amplitudes (A 1 and A 2 ) for these latter phases represented 7 Ϯ 0.6% and 5.5 Ϯ 0.4% of the decline in FRET. However, Fig. 4C shows that simultaneous addition of PTH(1-34) TMR (3 M) and [Aib 1, 3 , M]PTH(1-14) (10 M) eliminated the second phase, whereas the first phase remained mostly unchanged (k obs ϭ 2.78 Ϯ 0.15 s Ϫ1 and a corresponding amplitude of A ϭ 6.5 Ϯ 0.7%, n ϭ 6). The subsequent removal of [Aib 1, 3 , M]PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) restored the full response seen with PTH(1-34) TMR alone (Fig. 4D) . These observations are consistent with a model where the interaction of [Aib 1, 3 , M]PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) to the receptor J-domain prevents the second PTH(1-34) TMR -binding event to take place. It also implies that residues in the 15-34 portion of PTH interact with the receptor N-domain and dictate the initial binding step. Taken together, these data support a model where the slower second step in agonist binding is consistent with a conformational change of the bound PTH(1-34) TMR accompanying the receptor switch.
Sequential Events in PTHR Signaling. Because most, if not all, of the hormone receptor associations and subsequent cell responses do not occur at equilibrium, the temporal resolution of such events in real time is important to understand how cell signaling proceeds. In Fig. 6A we show the dynamics of sequential events starting with PTH(1-34) binding followed by PTHR activation and cAMP response recorded at the single-cell level. The data for cAMP were obtained from FRET experiments using a cAMP sensor (Fig. 7) , and a representative example is shown in Fig. 6B . These data indicate that a first rapid binding event precedes receptor activation by PTH(1-34) and provide a glimpse of the sequential events occurring in real time for PTHR signaling at the single-cell level.
Conclusion
Several mutagenesis and photo-affinity cross-linking experiments led to a two-site mode of PTH(1-34) binding to PTHR. In this model the N terminus extracellular part of PTHR comprising Ϸ160 residues (the receptor N-domain) is the principal binding site for the carboxyl-terminal region 23-34 of PTH , whereas the extracellular loops and transmembrane helices of PTHR (the receptor J-domain) bind the N-terminal 1-19 domain of the hormone (22, 23) . Given that residues 1-3 in this latter domain are essential in inducing receptor activation (8) , PTH binding to the J-domain is thought to drive receptor activation and subsequent G protein coupling.
Direct recording of PTH(1-34) association to PTHR provided information on the mechanism of hormone binding to its receptor and established a relation between an early agonist-binding step and a second receptor activation step in living cells. The results presented here are consistent with the mechanistic model of Gensure et al. (24) , which proposes that the disordered N-terminal residues of PTH(1-34) might become conformationally constrained upon association to the receptor. Extending this hypothesis to our present data, we propose a model in Fig. 6C where PTH(1-34) initially binds to the receptor N-domain with fast kinetics strictly dependent on agonist concentrations (k obs Ϸ 10 6 M Ϫ1 ⅐s Ϫ1 ), and next binds the receptor J-domain to adopt an active conformation. This second event coincides with the slower (k obs Ϸ 1 s Ϫ1 ) turn-on switch of the receptor.
